Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
04 Oct 2022Poor glycaemic control tied to death risk in T2D patients with CKD
Poorly controlled glycosylated haemoglobin (HbA1c) levels appear to aggravate the risk of mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), a recent study has found. Glycaemic control is not associated with progression to end-stage kidney disease (ESKD).
Poor glycaemic control tied to death risk in T2D patients with CKD
04 Oct 2022POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC
In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).
POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC
04 Oct 2022ADT suppresses levels of several androgen precursor steroids
In prostate cancer patients, the initiation of androgen deprivation therapy (ADT) lowers the concentrations of 13 circulating steroids, according to a new study.
ADT suppresses levels of several androgen precursor steroids
04 Oct 2022Why do psoriasis patients report better QoL amid COVID-19?
Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.
Why do psoriasis patients report better QoL amid COVID-19?
04 Oct 2022Add-on apatinib puts brakes on disease progression in advanced TNBC
The addition of apatinib to vinorelbine appears to prolong progression-free survival in patients with advanced triple-negative breast cancer (TNBC) with failed first- or second-line treatment, as shown in the results of a phase II study.